for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Inhibikase Therapeutics Inc

IKT.OQ

Latest Trade

2.48USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.21

 - 

11.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.48
Open
--
Volume
--
3M AVG Volume
11.16
Today's High
--
Today's Low
--
52 Week High
11.80
52 Week Low
2.21
Shares Out (MIL)
25.13
Market Cap (MIL)
62.33
Forward P/E
-3.06
Dividend (Yield %)
--

Next Event

Q1 2022 Inhibikase Therapeutics Inc Earnings Release

Latest Developments

More

Inhibikase Therapeutics Prices Follow-On Public Offering Of Common Stock

Inhibikase Therapeutics Inc Files For Offering Of Up To 8 Mln Shares Of Common Stock

Inhibikase Therapeutics Reports Q1 Loss Per Share Of $0.26

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Inhibikase Therapeutics Inc

Inhibikase Therapeutics Inc. is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The Company’s lead product candidate, IkT-148009 is for the treatment of PD, and for the treatment of gastrointestinal (GI), complications that arise as early symptoms of PD in patients. The Company’s kT-148009, is a brain penetrant c-Abl protein kinase inhibitor that halts disease progression and reverses functional loss in the brain and reverses neurological dysfunction in the GI tract. The Company’s products candidate also include IKT-001Pro, which is a prodrug of the anticancer agent Imatinib, and used as a treatment for stable-phase chronic myelogenous leukemia (CML), and IKT-01427 for progressive multifocal leukoencephalopathy (PML).

Industry

Biotechnology & Drugs

Contact Info

3350 Riverwood Parkway Se, Suite 1900

ATLANTA, GA

30339

United States

+1.678.3923419

http://www.inhibikase.com/

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2021(E)

0.0K
EPS (USD)

2021(E)

-0.685
Price To Earnings (TTM)
--
Price To Sales (TTM)
33.97
Price To Book (MRQ)
3.10
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
15.48
LT Debt To Equity (MRQ)
3.10
Return on Investment (TTM)
-253.43
Return on Equity (TTM)
-82.90

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up